DEI Biopharma introduces cutting-edge biotechnology products, including mRNA vaccines, biosimilars, gene, and cell therapy products alongside traditional pharmaceutical products to make Uganda self-sufficient in the healthcare field. Established on a 100-acre campus containing muliple manufacturing facilities making DEI Biopharma as the largest in Africa and the only company producing biological products including mRNA vaccines.
President Museveni of Uganda and Deputy President Ruto of Kenya visited the DEI Biopharma manufacturing facility and met with the technical teams from Spain, Italy, Sweden, and the USA to provide details about their role in the project. They toured the facility, along with the Minister of Science, Technology and Innovation, Dr. Monica Musenero, who assured full support of the Uganda and Kenya governments to expedite the completion of DEI Biopharma.
DEI Biopharma intends to produce an mRNA vaccine for COVID-19 within six months. In addition, it plans to create a consortium of African countries through WHO affiliation to become the leader in the vaccine supply for COVID-19 and many more such vaccines in the future.
DEI Biopharma has established a technology development program with Prof. Sarfaraz K. Niazi from the USA, and his technology company PharmSci that is providing technology for pharmaceutical and biopharmaceutical products and RNA Therapeutics that is providing turnkey technologhy of a COVID-19 mRNA vaccine. DEI Biopharma products will comply with regualtory requirements of the FDA and EMA. Member of Prof. Niazi’s team, KeyPlant’s David Lindholm defined their role as a fast provider of modular manufacturing systems enabling manufacaturing of mRNA vaccines within months in Uganda.
The TECO team led by the company President Mr. Mirco Pellacan from Italy and the BIORE team led by Dr. Lluis Adella from Spain are now completing a 16,000 square meter facility for many lifesaving products manufactured in Uganda and assured that the products manufactured by DEI Pharma will meet all global standards of quality.
DEI Biopharma will generate thousands of new high-paying jobs, provide every pharmaceutical and biopharmaceutical product needs of Ugandans and for the rest of the citizens of Africa, a role model operation that will earn billions of dollars of foreign exchange for Uganda.